NFKB1抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using NFKB1 mouse mAb against K562 (1), Jurkat (2), A431 (3), Hela (4), THP-1 (5) and MCF-7 (6) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using NFKB1 mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human prostate tissues (left) and bladder cancer tissues (right) using NFKB1 mouse mAb with DAB staining.    

  
  

**Background of NFKB1 Antibodies**

NFKB1 (nuclear factor kappa B subunit 1) is a critical component of the NF-κB transcription factor family, which regulates genes involved in immune responses, inflammation, cell survival, and proliferation. The NFKB1 gene encodes the p105 precursor protein, which is processed into the mature p50 subunit. p50 forms homodimers or heterodimers (e.g., with RelA/p65) to bind DNA and modulate target gene expression. In resting cells, NF-κB complexes are sequestered in the cytoplasm by inhibitory proteins like IκB. Upon stimulation (e.g., cytokines, pathogens, or stress signals), IκB is degraded, allowing NF-κB translocation to the nucleus.

NFKB1 antibodies are essential tools for studying the expression, localization, and function of the p50/p105 proteins. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). They help researchers investigate NF-κB signaling dysregulation in diseases like cancer, autoimmune disorders, and chronic inflammation. Commercial NFKB1 antibodies are often validated for specificity against recombinant proteins or cell lines with NFKB1 knockout.

Antibody selection depends on the target epitope (e.g., N-terminal, C-terminal, or phosphorylated sites) and application requirements. For example, antibodies recognizing the N-terminal region of p50 are ideal for detecting active NF-κB dimers, while those targeting the C-terminal ankyrin-repeat domain of p105 may distinguish precursor forms. Proper validation ensures accurate detection, as cross-reactivity with other NF-κB subunits (e.g., p52 from NFKB2) can occur. Understanding NFKB1’s role in cellular pathways and disease mechanisms continues to drive the development and application of these antibodies.